Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Merck's colorectal cancer therapy fails late-stage trial
Merck said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial testing it in previously treated patients with a type of colorectal cancer. Th
Merck says trial of combination treatment for colon cancer failed to meet main goal
Merck & Co.’s said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet the main goal of overall survival (OS) as a treatment for a type of colon cancer.
Merck's Keytruda-LAG-3 combo fails to tame tough colorectal cancer in phase 3
An attempt by Merck & Co. to unlock the microsatellite stable (MSS) metastatic colorectal cancer market has ended in failure. | An attempt by Merck & Co. to unlock the microsatellite stable metastatic colorectal cancer market has ended in failure.
Merck's Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study
Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of favezelimab and pembrolizumab versus the standard of care for pretreated patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).
Merck fails in late-stage trial for Keytruda combo in colon cancer
Merck (MRK) stock is in focus as a Phase 3 trial for its cancer drug Keytruda in colorectal cancer patients did not meet primary endpoint. Read more here.
MRK's Keytruda Combo Fails in Phase III Colorectal Cancer Study
Merck MRK announced data from the phase III KEYFORM-007 study, which evaluated a fixed-dose combination of its anti-LAG-3 antibody, favezelimab and its blockbuster anti-PD-1 therapy, Keytruda in pre-treated patients with PD-L1 positive microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
1h
on MSN
Merck snaps six straight sessions of losses
Shares of Merck (NYSE:MRK) traded marginally higher on Friday after falling from a high of $119.38 from the past seven ...
1d
Merck & Co. Inc. stock underperforms Thursday when compared to competitors
Shares of Merck & Co. Inc. MRK slipped 1.43% to $113.09 Thursday, on what proved to be an all-around favorable trading ...
FierceBiotech
1d
Merck bags options on Evaxion's AI-designed vaccines, offering small upfront and big back end
Merck & Co. has picked up options on two Evaxion vaccine candidates, paying $3.2 million and dangling more than $1 billion in ...
11h
Evaxion Biotech Gains Buy Rating Amid Merck Collaboration and AI-Driven Vaccine Development Prospects
Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on Evaxion Biotech (EVAX – Research Report). The ...
16h
Merck KGaA's (ETR:MRK) earnings growth rate lags the 11% CAGR delivered to shareholders
When we invest, we're generally looking for stocks that outperform the market average. Buying under-rated businesses ...
13d
on MSN
Where Will Merck Stock Be in 5 Years?
Merck ( MRK 0.53%) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...
10h
on MSN
Merck & Co., Inc. (MRK): An Undervalued Wide Moat Stock to Buy According to Analysts
We recently compiled a list of the 10 Undervalued Wide Moat Stocks to Buy According to Analysts. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the ...
2d
FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients
On Thursday, 26 September, the FDA's Oncologic Drugs Advisory Committee will discuss the use of immune checkpoint inhibitors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
New York Stock Exchange
Keytruda
S&P 500 Index
Pembrolizumab
European Union
Feedback